Growth Metrics

Amneal Pharmaceuticals (AMRX) EPS (Weighted Average and Diluted) (2018 - 2025)

Historic EPS (Weighted Average and Diluted) for Amneal Pharmaceuticals (AMRX) over the last 8 years, with Q3 2025 value amounting to $0.01.

  • Amneal Pharmaceuticals' EPS (Weighted Average and Diluted) fell 7366.28% to $0.01 in Q3 2025 from the same period last year, while for Sep 2025 it was $0.02, marking a year-over-year increase of 10235.29%. This contributed to the annual value of -$0.38 for FY2024, which is 2066.95% up from last year.
  • Per Amneal Pharmaceuticals' latest filing, its EPS (Weighted Average and Diluted) stood at $0.01 for Q3 2025, which was down 7366.28% from $0.07 recorded in Q2 2025.
  • Amneal Pharmaceuticals' 5-year EPS (Weighted Average and Diluted) high stood at $0.1 for Q2 2021, and its period low was -$0.8 during Q2 2022.
  • Its 5-year average for EPS (Weighted Average and Diluted) is -$0.08, with a median of -$0.01 in 2022.
  • Over the last 5 years, Amneal Pharmaceuticals' EPS (Weighted Average and Diluted) had its largest YoY gain of 40000.0% in 2023, and its largest YoY loss of 176690.97% in 2023.
  • Amneal Pharmaceuticals' EPS (Weighted Average and Diluted) (Quarter) stood at -$0.04 in 2021, then grew by 25.0% to -$0.03 in 2022, then tumbled by 1766.91% to -$0.56 in 2023, then skyrocketed by 87.99% to -$0.07 in 2024, then skyrocketed by 114.87% to $0.01 in 2025.
  • Its last three reported values are $0.01 in Q3 2025, $0.07 for Q2 2025, and $0.04 during Q1 2025.